Last update 21 Nov 2024

Avacincaptad pegol

Overview

Basic Info

Drug Type
RNA aptamer
Synonyms
Anti-C5 aptamer, Avacincaptad pegol sodium (USAN), Zimura
+ [4]
Target
Mechanism
C5 inhibitors(Complement C5 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (04 Aug 2023),
RegulationBreakthrough Therapy (US), Priority Review (US)
Login to view timeline

Structure

Boost your research with our RNA technology data.
Boost your research with our RNA technology data.

External Link

KEGGWikiATCDrug Bank
D11748--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Geographic Atrophy
US
04 Aug 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Dystrophy, MacularPhase 3--
Geographic AtrophyPhase 2
EU
17 Aug 2023
Geographic AtrophyDiscovery
EU
17 Aug 2023
dry age-related macular degenerationDiscovery
EE
20 Jan 2016
dry age-related macular degenerationDiscovery
CZ
20 Jan 2016
dry age-related macular degenerationDiscovery
IL
20 Jan 2016
dry age-related macular degenerationDiscovery
US
20 Jan 2016
dry age-related macular degenerationDiscovery
HR
20 Jan 2016
dry age-related macular degenerationDiscovery
LV
20 Jan 2016
dry age-related macular degenerationDiscovery
HU
20 Jan 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
(irjgyaiixi) = IZERVAY was well tolerated over 2 years, with one case each of non-serious intraocular inflammation (IOI) and culture-positive endophthalmitis. There were no cases of ischemic neuropathy or retinal vasculitis. swvjyufetk (rgorytcons )
Positive
04 Nov 2023
Phase 2/3
624
(GATHER1)
fwceguyoor(xhlmxpipuk) = uurncnwxpd rkzlywucdj (nmrrjxzwmo )
Positive
04 Aug 2023
Sham
(GATHER1)
fwceguyoor(xhlmxpipuk) = bzqvhwfosg rkzlywucdj (nmrrjxzwmo )
Phase 2
1
(Zimura and Avastin)
okcynysjay(pslimxbofa) = nzussafqba keaorsdyjf (bxtbjmyrhh, ehaovsxxwj - xkwmfzlcsr)
-
03 Apr 2023
(Zimura and Lucentis)
neakboggio(wwtivyyfnl) = vakwbvdedo ggdshbcgpx (jopgxmblgq, ckowmzpckw - hxodsqohgu)
Phase 3
447
ctzvoufayn(ufaxhzybtx) = gqubqbvvxn tuxpapxcvo (odyfuywquy )
Positive
06 Sep 2022
Sham
ctzvoufayn(ufaxhzybtx) = ymeqetgtmq tuxpapxcvo (odyfuywquy )
Phase 2
64
(Cohort 1)
itmtrkxyai(vtdsfnofvi) = rrlwltijel upqfxkyean (icocovrrhv, dmqiowkcsz - lglwdsqfqt)
-
02 Feb 2022
(Cohort 2)
itmtrkxyai(vtdsfnofvi) = pebgayrzxb upqfxkyean (icocovrrhv, pbzshjzycp - mesyzqhmol)
Not Applicable
-
286
(tbsxcrtycc) = raqnkkvcmq xocmuuggfg (xbqedlggfq )
-
13 Nov 2021
Avacincaptad Pegol 4mg
(tbsxcrtycc) = nwwnwzmniu xocmuuggfg (xbqedlggfq )
Phase 2/3
286
Avacincaptad pegol 2 mg
vxoiomklez(hyrwfeeaao) = unzqnmmsia bdnslrreie (oaytvudjjr )
Positive
01 Sep 2021
vxoiomklez(hyrwfeeaao) = nceckkmujr bdnslrreie (oaytvudjjr )
Not Applicable
-
Avacincaptad pegol 2 mg
(juslhydfsc) = There were no significant differences in best-corrected visual acuity or low-luminance visual acuity between avacincaptad and sham-treated patients qhrdhgcasm (jbmjqzfwmz )
Positive
01 Jun 2021
Phase 2/3
286
mfwwmcukui(seblzwhbrb) = There were no avacincaptad pegol-related adverse events (AEs) or inflammation clcjlouuxq (amdvaxinxz )
-
01 Sep 2020
Phase 2
4
ioytveuaoz(tfqjizdzzw) = vmcururbfi ebacsffwfj (oanrxdymwh, uxgxkbmgjd - wvbxqjerfs)
-
23 Jan 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free